609.F ABIONYX PHARMA SA EO-05

Healthcare Biotechnology Frankfurt Exchange
1.59 EUR
Close of Nov 11, 2026
1.37 4.26
Market cap
EUR 69.5M
P/E
-
P/B
4.26x
ROE
-123.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 609.F undervalued?

Graham number

The Graham number of ABIONYX PHARMA SA EO-05 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABIONYX PHARMA SA EO-05 fundamental analysis

No fundamental analysis for ABIONYX PHARMA SA EO-05 yet.

ABIONYX PHARMA SA EO-05 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABIONYX PHARMA SA EO-05

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase …

Full company profile